Emerging evidence indicates that baseline use of certain concomitant drugs may affect the efficacy of immune checkpoint inhibitors (ICIs), including PD‐1, PD‐L1, and CTLA‐4 inhibitors, in patients with cancer. Here, CD274 is linked to cancer.